Kamada (KMDA) Interest Expenses (2012 - 2026)
Kamada (KMDA) posted Interest Expenses of -$188000.0 for Q1 2026, up 27.41% on a QoQ basis from -$259000.0 in Q4 2025, and up 2.08% year-over-year from -$184163.3 in Q1 2025.
Kamada (KMDA) Interest Expenses (2012 - 2026) Analysis & Trends
Kamada's Interest Expenses history runs 15 years deep, the most recent figure standing at -$188000.0 for Q1 2026.
- Quarterly Interest Expenses rose 2.08% year-over-year to -$188000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$876000.0 (down 27.88% YoY) and the FY2025 annual result came in at -$864000.0, down 230.91% from the prior year.
- Interest Expenses was -$188000.0 for Q1 2026 at Kamada, up from -$259000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at -$211.0 in Q3 2022 and bottomed at -$439000.0 in Q2 2023.
- A 5-year average of -$197335.9 and a median of -$189000.0 in 2024 frame the typical range for Interest Expenses.
- Peak annual rise in Interest Expenses reached 99.74% in 2023, while the deepest fall reached 191843.13% in 2023.
- Kamada's Interest Expenses stood at -$331000.0 in 2022, then soared by 76.13% to -$79000.0 in 2023, then plunged by 139.24% to -$189000.0 in 2024, then plunged by 37.04% to -$259000.0 in 2025, then rose by 27.41% to -$188000.0 in 2026.
- Business Quant data shows KMDA's Interest Expenses at -$188000.0 in Q1 2026, -$259000.0 in Q4 2025, and -$221000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.77 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Kamada | 405.83 Mn | 332.68 Mn | 19.12 Mn | -188,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -188,000.00 |
| Mar 31, 2026 | -188,000.00 |
| Dec 31, 2025 | -259,000.00 |
| Dec 31, 2025 | -259,000.00 |
| Sep 30, 2025 | -221,000.00 |
| Sep 30, 2025 | -221,000.00 |
| Jun 30, 2025 | -208,000.00 |
| Jun 30, 2025 | -208,000.00 |
| Mar 31, 2025 | -192,000.00 |
| Mar 31, 2025 | -192,000.00 |
| Dec 31, 2024 | -189,000.00 |
| Dec 31, 2024 | -189,000.00 |
| Sep 30, 2024 | -167,000.00 |
| Sep 30, 2024 | -167,000.00 |
| Jun 30, 2024 | -137,000.00 |
| Jun 30, 2024 | -137,000.00 |
| Mar 31, 2024 | -159,000.00 |
| Mar 31, 2024 | -159,000.00 |
| Dec 31, 2023 | -79,000.00 |
| Dec 31, 2023 | -79,000.00 |